MENU
+Compare
BEAM
Stock ticker: NASDAQ
AS OF
Aug 13, 04:59 PM (EDT)
Price
$17.52
Change
+$0.66 (+3.91%)
Capitalization
1.71B

BEAM Beam Therapeutics Forecast, Technical & Fundamental Analysis

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases... Show more

BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BEAM with price predictions
Aug 11, 2025

BEAM's Stochastic Oscillator sits in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BEAM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 182 cases where BEAM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAM as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BEAM turned negative on July 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

BEAM moved below its 50-day moving average on August 06, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BEAM crossed bearishly below the 50-day moving average on August 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BEAM broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (18.461). P/E Ratio (0.000) is within average values for comparable stocks, (53.401). BEAM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.822). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (24.876) is also within normal values, averaging (286.886).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BEAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BEAM is expected to report earnings to rise 5.00% to -104 cents per share on November 10

Beam Therapeutics BEAM Stock Earnings Reports
Q3'25
Est.
$-1.05
Q2'25
Beat
by $0.11
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.18
Q3'24
Beat
by $0.01
The last earnings report on August 05 showed earnings per share of -100 cents, beating the estimate of -111 cents. With 1.55M shares outstanding, the current market capitalization sits at 1.71B.
A.I. Advisor
published General Information

General Information

a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
238 Main Street
Phone
+1 857 327-8775
Employees
436
Web
https://www.beamtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OTCIX33.38-0.05
-0.15%
MFS Mid Cap Growth I
IACIX10.77-0.04
-0.37%
VY® American Century Sm-Mid Cp Val I
CCTRX12.58-0.05
-0.40%
Columbia Small Cap Value II R
LZESX12.29-0.06
-0.49%
Lazard International Equity Select Open
GOFFX50.53-0.27
-0.53%
Invesco Global Opportunities R5

BEAM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-2.58%
CRSP - BEAM
68%
Closely correlated
N/A
NTLA - BEAM
65%
Loosely correlated
-0.46%
RXRX - BEAM
64%
Loosely correlated
N/A
SYRE - BEAM
59%
Loosely correlated
+0.07%
DNLI - BEAM
57%
Loosely correlated
-0.29%
More

Groups containing BEAM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-2.58%
BEAM
(2 stocks)
87%
Closely correlated
+2.60%